Inflammation and diabetic nephropathy

被引：231

作者：

Mora C. ^{[1
]}

Navarro J.F. ^{[1
]}

机构：

[1] Nephrology Service, University Hospital Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife

来源：

Current Diabetes Reports | 2006年 / 6卷 / 6期

关键词：

Diabetic Nephropathy; Renal Injury; Pentoxifylline; Urinary Albumin Excretion; European Prospective Investigation Into Cancer;

D O I：

10.1007/s11892-006-0080-1

中图分类号：

学科分类号：

摘要：

Diabetic nephropathy has become the main cause of renal failure, but unfortunately the intimate mechanisms leading to the development and progression of renal injury are not yet fully known. Activated innate immunity and inflammation are relevant factors in the pathogenesis of diabetes. Moreover, different inflammatory molecules, including chemokines, adhesion molecules, and proinflammatory cytokines, may be critical factors in the development of microvascular diabetic complications, including nephropathy. This new pathogenic perspective leads to important therapeutic considerations, with new pathogenic pathways becoming important therapeutic targets that can be translated into clinical treatments for diabetic nephropathy. Copyright © 2006 by Current Science Inc.

引用

页码：463 / 468

页数：5

共 78 条

[11]

Festa A., D'Agostino R., Tracey R.P., Haffner S.M., Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study, Diabetes, 51, pp. 1131-1137, (2002)

[12]

Spranger J., Kroke A., Mohlig M., Et al., Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam study, Diabetes, 52, pp. 812-817, (2003)

[13]

Yuan M., Konstantopoulos N., Lee J., Et al., Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta, Science, 293, pp. 1673-1677, (2001)

[14]

Freeman D.J., Norrie J., Naveed S., Et al., Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study, Circulation, 103, pp. 357-362, (2001)

[15]

McFarlane S.I., Muniyappa R., Francisco R., Stowers J.R., Pleiotropic effects of statins: Lipid reduction and beyond, J Clin Endocrinol Metab, 87, pp. 1451-1458, (2002)

[16]

Ricote M., Li A.C., Wilson T.M., Et al., The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation, Nature, 391, pp. 79-82, (1998)

[17]

Jiang C., Ting A.T., Seed B., PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines, Nature, 391, pp. 82-85, (1998)

[18]

Anderson Jr. D.C., Pharmacologic prevention or delay of type 2 diabetes mellitus, Ann Pharmacother, 39, pp. 102-109, (2005)

[19]

Crook M., Type 2 diabetes mellitus: A disease of the innate immune system? An update, Diabet Med, 21, pp. 203-207, (2004)

[20]

Maffei M., Fei H., Lee G.H., Et al., Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus, Proc Natl Acad Sci U S A, 92, pp. 6957-6960, (1995)

← 1 2 3 4 5 6 7 8 →